Immune Design Corp. Form 8-K July 29, 2014

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

July 29, 2014

IMMUNE DESIGN CORP.

(Exact name of registrant as specified in its charter)

Delaware (state or other jurisdiction

001-36561 (Commission

26-2007174 (I.R.S. Employer

of incorporation)

File Number)

Identification No.)

1616 Eastlake Ave. E., Suite 310

Seattle, Washington (Address of principal executive offices) 98102 (Zip Code)

Registrant s telephone number, including area code: (206) 682-0645

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

Amendment and Restatement of Certificate of Incorporation

On July 29, 2014, Immune Design Corp. (the Company) filed an amended and restated certificate of incorporation (the Restated Certificate) with the Secretary of State of the State of Delaware in connection with the closing of the Company s initial public offering of shares of its common stock. The Company s board of directors and stockholders approved the Restated Certificate on April 22, 2014 and July 14, 2014, respectively, to be effective immediately prior to the closing of the initial public offering.

The foregoing description is qualified in its entirety by reference to the Restated Certificate, a copy of which is attached hereto as Exhibit 3.1 and is incorporated herein by reference.

Amendment and Restatement of Bylaws

Effective as of July 29, 2014, the Company adopted amended and restated bylaws (the Restated Bylaws) in connection with the closing of the Company s initial public offering of shares of its common stock. The Company s board of directors and stockholders approved the Restated Bylaws on April 22, 2014 and July 14, 2014, respectively, to be effective immediately prior to the closing of the initial public offering.

The foregoing description is qualified in its entirety by reference to the Restated Bylaws, a copy of which is attached hereto as Exhibit 3.2 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

No.	Description
3.1	Amended and Restated Certificate of Incorporation of the Company.
3.2	Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.4 to the Company s Registration Statement on Form S-1, as amended, filed with the Securities and Exchange Commission on June 23, 2014).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IMMUNE DESIGN CORP.

By: /s/ Carlos Paya, M.D., Ph.D. Carlos Paya, M.D., Ph.D. President and Chief Executive Officer

Dated: July 29, 2014

EXHIBIT INDEX

Exhibit

No. Description 3.1 Amended and Restated Certificate of Incorporation of the Company. 3.2 Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.4 to the Company s Registration Statement on Form S-1, as amended, filed with the Securities and Exchange Commission on June 23, 2014).